Hitachi, Ltd.

Hokkaido University

Nihon Medi-physics Company, Limited

Yuji Kuge

Takeshi Sakamoto

Hiroko Hanzawa

Naomi Manri

Masato Kiriu

Yuki Okumura

Hiroki Matsumoto

Norihito Nakata

Soichi Nakamura

Eriko Nagata

Songji Zhao

Norifumi Abo

Ken-Ichi Nishijima

A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[F]fluoropropyl)-2-nitroimidazole ([F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [F]DiFA from a labeling precursor compound for [F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.

Method for producing radiopharmaceutical composition

It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

Method for evaluating ischemic heart disease by assaying complement factor H or D

The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result.

Method for evaluating atherosclerotic lesion, and kit

Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

Evaluation method for arteriosclerosis

The present invention is a compound represented by the following formula (1) or a salt thereof. In the formula (1), Rdenotes a hydrogen atom, a methyl group, or a hydroxymethyl group, and n is an integer of 1 or 2. 

Radioactive fluorine-labeled compound

A method is provided for diagnosing or predicting atherosclerosis with the use of, as indicators, markers (factors) that allow early detection and progression prediction of the disease and a method for evaluating preventive or therapeutic effects. In one form, the present method includes detecting CD166 (ALCAM) level in a sample of a subject such as human. Another aspect of the present method includes evaluating preventive or therapeutic effects of a compound on atherosclerosis. A kit and an apparatus for carrying out such methods is also provided.

Growing community of inventors

Sapporo, Japan

Yuji Kuge